Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Augmentation for SSRI-Resistant Civilian PTSD
NCT00133822Phase 2Completed
- Sponsor
- Emory University
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Risperidone Augmentation with Placebo Augmentation (2 arms). Primary endpoint: Remission of symptoms at 16 weeks. Started Apr 2004; status: completed.
02
Drugs
risperidone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT00133822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133822.